

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 October 2003 (30.10.2003)

PCT

(10) International Publication Number
WO 03/089413 A1


- (51) International Patent Classification⁷: C07D 211/58, 491/22, A61K 31/4468, 31/4745, A61P 35/00
- (21) International Application Number: PCT/US03/11551
- (22) International Filing Date: 16 April 2003 (16.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/373,727 17 April 2002 (17.04.2002) US
- (71) Applicant (for all designated States except US): PHARMACIA CORPORATION [US/US]; Global Patent Department, 575 Maryville Centre Drive, 5th Floor, Mail Zone 1006, St. Louis, MO 63006 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): HENEGAR, Kevin, E. [US/US]; 6136 Sablewood Circle, Portage, MI 49024 (US).
- (74) Agents: FORBES, James, C. et al.; Pharmacia Corporation, P.O. Box 5110, Chicago, IL 60680 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACIA CORPORATION



(57) Abstract: Novel compounds are provided having formula (I) and salts thereof, where R¹ is hydrogen, an alkyl, aralkyl, hydroxymethyl, carboxymethyl, acyloxymethyl or trialkylsilyl group, or a group -CH₂NR³R⁴ where N is a linking nitrogen atom and where (a) R³ and R⁴ are independently selected from hydrogen and alkyl, alkenyl, hydroxyalkyl and alkoxyalkyl groups; (b) R³ is hydrogen or an alkyl, alkenyl, hydroxyalkyl or alkoxyalkyl group, and R⁴ is -COR⁵ where R⁵ is hydrogen or an alkyl, alkenyl, hydroxyalkyl or alkoxyalkyl group; or (c) R³ and R⁴ taken together

with the linking nitrogen atom form a saturated 3- to 7-member heterocyclic group. These compounds are useful intermediates in a process to prepare camptothecin derivatives including the anti-cancer drug irinotecan.

WO 03/089413 A1


COMPOUNDS USEFUL IN PREPARING CAMPTOTHECIN DERIVATIVES


FIELD OF THE INVENTION

[0001] The present invention relates to manufacture of camptothecin derivatives therapeutically useful as anti-cancer drugs, in particular the camptothecin derivative irinotecan and salts thereof. More particularly, the invention relates to a novel intermediate and to a process for preparing a camptothecin derivative via that intermediate.

BACKGROUND OF THE INVENTION

[0002] U.S. Patent No. 6,121,451 to Henegar & Sih, incorporated herein by reference, discloses a process for preparing the antineoplastic drug irinotecan, also known as 7-ethyl-10-hydroxycamptothecin 10-[1,4'-bipiperidine]-1'-carboxylate or CPT-11 free base. In the disclosed process, a compound therein identified as 14CPT (I) is first reacted with 1-(4-hydroxy-2-aminophenyl)-1-propanone (II) to form an intermediate compound (III), which is then reacted with 4-piperidinopiperidinecarbamyl chloride (IV) to produce CPT-11 free base (V), as shown schematically below.






[0003] Alternative materials and methods for preparing irinotecan and other therapeutically useful camptothecin derivatives are desired in the art.

SUMMARY OF THE INVENTION

[0004] Novel compounds are now provided, having the formula (VI)




where R^1 is hydrogen, an alkyl, aralkyl, hydroxymethyl, carboxymethyl, acyloxymethyl or trialkylsilyl group, or a group $-\text{CH}_2\text{NR}^3\text{R}^4$ where N is a linking nitrogen atom and where R^3 and R^4 are as defined hereinbelow. Also provided are salts of the compounds of formula (VI) with pharmaceutically acceptable anions.

[0005] Options for R^3 and R^4 are:

- (a) R^3 and R^4 are independently selected from hydrogen and alkyl, alkenyl, hydroxyalkyl and alkoxyalkyl groups;
- (b) R^3 is hydrogen or an alkyl, alkenyl, hydroxyalkyl or alkoxyalkyl group, and R^4 is $-\text{COR}^5$ where R^5 is hydrogen or an alkyl, alkenyl, hydroxyalkyl or alkoxyalkyl group; or
- (c) R^3 and R^4 taken together with the linking nitrogen atom form a saturated 3- to 7-member heterocyclic group.

[0006] Compounds of the invention are useful intermediates in a process to prepare

camptothecin derivatives of formula (VII)



where R^1 is as defined above and R^2 is hydrogen or an alkyl group, preferably hydrogen.

[0007] In a preferred embodiment R^1 is an ethyl group and R^2 is hydrogen. According to this embodiment, the novel compound of formula (VI) is 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate, which is a useful intermediate in a process to prepare irinotecan (V) and salts thereof, for example the hydrochloride salt CPT-11. Thus, according to another embodiment of the invention, a process is provided comprising a step of reacting 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate with the compound of formula (I) above to form irinotecan.

[0008] In yet another embodiment of the invention, a process is provided for preparing a compound of formula (VI). This process can be illustrated with respect to the compound of formula (VI) where R^1 is an ethyl group, *i.e.*, 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate. In this case the process comprises a step of reacting 1-(4-hydroxy-2-aminophenyl)-1-propanone (II) with 4-piperidinopiperidinecarbonyl chloride (IV) to form 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate. By appropriate modification of compound (II) one of skill in the art will be able to make other compounds of formula (VI) of the invention.

[0009] Typically, an irinotecan or CPT-11 product prepared by a process using 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate will contain at least a detectable amount of that compound. Thus, in yet another embodiment of the invention, there is provided a pharmaceutical composition comprising a therapeutically effective amount of irinotecan and/or a salt thereof and at least a detectable amount of 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate and/or a salt thereof. By its presence in a

detectable amount, 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate is useful as an analytical marker for a product of (a) a process involving that compound as a reagent or (b) a process involving as reagents 1-(4-hydroxy-2-aminophenyl)-1-propanone and 4-piperidinopiperidinecarbonyl chloride under circumstances permitting these reagents to react to form 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate.

DETAILED DESCRIPTION OF THE INVENTION

[0010] R^1 in a compound of formula (VI) of the present invention is hydrogen, an alkyl, aralkyl, hydroxymethyl, carboxymethyl, acyloxymethyl or trialkylsilyl, *e.g.*, trimethylsilyl, group, or a group $-CH_2NR^3R^4$ where N is a linking nitrogen atom and where (a) R^3 and R^4 are independently selected from hydrogen and alkyl, alkenyl, hydroxyalkyl and alkoxyalkyl groups; (b) R^3 is hydrogen or an alkyl, alkenyl, hydroxyalkyl or alkoxyalkyl group, and R^4 is $-COR^5$ where R^5 is hydrogen or an alkyl, alkenyl, hydroxyalkyl or alkoxyalkyl group; or (c) R^3 and R^4 taken together with the linking nitrogen atom form a saturated 3- to 7-member heterocyclic group. Also provided are salts of the compounds of formula (VI) with pharmaceutically acceptable anions.

[0011] Alkyl, alkenyl, aralkyl, acyl and alkoxy groups herein, unless otherwise defined, have 1–30, preferably 1–18, more preferably 1–6, carbon atoms. In particularly preferred compounds of formula (VI), R^1 is a C_{1-4} alkyl, most preferably an ethyl, group.

[0012] Compounds of formula (VI) above exist in free base form and in various pharmaceutically acceptable salt forms, which are embodiments of the present invention.

[0013] Pharmaceutically acceptable salts of compounds of formula (VI) include without restriction salts of the following acids: hydrochloric, hydrobromic, sulfuric, methanesulfonic, phosphoric, nitric, benzoic, citric, tartaric, fumaric and maleic acids, and mono- and dicarboxylic acids of formula $CH_3-(CH_2)_n-COOH$ and $HOOC-(CH_2)_n-COOH$ where n is 0 to 4, for example malonic acid. The hydrochloride salt is particularly preferred.

[0014] In another embodiment of the invention a process is provided comprising a step of reacting 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate (the compound of formula (VI) where R^1 is ethyl) or a salt thereof with 14CPT ((4S)-4-ethyl-7,8-dihydro-4-hydroxy-(1H)-pyrano[3,4-f]indolizine-3,6,10(4H)-trione), the compound of formula (I) above, to form irinotecan or the corresponding salt thereof.

[0015] This reaction can illustratively be carried out by heating 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate and 14CPT together in a suitable solvent, for example acetic acid. The product of the reaction can then be purified by a suitable chromatographic method and isolated, for example by crystallization from a suitable solvent medium. An illustrative example of a process of this embodiment of the invention is provided below in Example 2.

[0016] Accordingly, the novel compound 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate or a salt thereof is a useful intermediate in a manufacturing process for irinotecan or a salt thereof.

[0017] Optionally, irinotecan or a salt thereof prepared by a process of the invention can be further processed to yield other camptothecin derivatives by methods known in the art. For example, irinotecan prepared as described herein can be subjected to hydrolysis in an acid medium, for example in presence of hydrochloric acid, to yield 7-ethyl-10-hydroxycamptothecin.

[0018] In yet another embodiment of the invention a process for preparing 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate is provided, comprising a step of reacting 1-(4-hydroxy-2-aminophenyl)-1-propanone (II) with 4-piperidinopiperidinecarbonyl chloride (IV).

[0019] This reaction can illustratively be carried out by mixing known compounds (II) and (IV) together in a suitable solvent, for example pyridine. Alternatively, a solvent system comprising methylene chloride, tetrahydrofuran, acetonitrile or the like together with a suitable base such as triethylamine or diisopropylethylamine can be used as a medium for the reaction. The product of the reaction can then be subjected to isolation and purification steps, illustratively those described in Example 1 below, to yield 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate.

[0020] In yet another embodiment of the invention, a pharmaceutical composition or drug substance is provided comprising (a) irinotecan and/or one or more pharmaceutically acceptable salts thereof in a therapeutically effective total amount, and (b) 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate and/or one or more salts thereof in at least a detectable amount. By a "therapeutically effective" amount of irinotecan or salt thereof is meant an amount useful as at least a single dosage amount for treatment of cancer. By a

“detectable” amount of 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate is meant a sufficient amount to give positive identification but not necessarily quantitation of the compound by any suitable analytical technique, for example HPLC.

[0021] Preferably according to this embodiment, the drug substance comprises not more than about 5%, more preferably not more than about 2.5% and most preferably not more than about 1% by weight of 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate. The presence of 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate in a drug substance of this embodiment is useful as an analytical marker, providing evidence, for example, that the irinotecan with which it occurs has been prepared by (a) a process involving 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate as a reagent (e.g., the process described above and illustrated in Example 2 below) or (b) a process involving as reagents compounds (II) and (IV) under circumstances permitting these compounds to react to form 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate.

EXAMPLES

[0022] The following examples illustrate aspects of the present invention but are not to be construed as limitations.

Example 1: 4-Amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate

[0023] A solution of 3.26 g (19.6 mmol) 2-amino-5-hydroxypropiophenone and 6.97 g (26.1 mmol) 4-piperidinopiperidinecarbonyl chloride hydrochloride in 35 ml pyridine was stirred at room temperature for 13 hours. The pyridine was then evaporated and 20 ml water and 120 ml ethyl acetate were added. The resulting organic phase was separated and dried over sodium sulfate. The sodium sulfate was removed by filtration and 10 g silica-60 was added to the filtrate, which was stirred to form a slurry. The slurry was loaded onto a column of 20 g silica-60 (230-400 mesh) and eluted with a 95:5 (v/v) methylene chloride/methanol mixture. The resulting product fractions were combined and evaporated to provide a residue, which was then redissolved in a mixture of 20 ml methylene chloride and 50 ml heptane. The resulting solution was evaporated to yield 6.22 g of 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate as a yellow-green solid, melting point 132.0–133.5°C.

[0024] ¹H NMR (400.13 MHz, CDCl₃) δ 7.46 (s, 1H) 7.03 (d, 1H, J=8.8 Hz), 6.64 (d, 1H, J=8.8 Hz), 6.2 (s, 2H), 4.35 (s, 2H), 2.95 (q, 2H, J=7.2 Hz), 2.5–2.9 (m, 9H), 1.4–1.7

(m, 8H), 1.20 (t, 3H, J=7.6 Hz).

[0025] ^{13}C NMR (75.47 MHz, CDCl_3) δ 204.39, 155.88, 149.69, 142.2, 130.28, 124.84, 119.71, 119.16, 85.91, 64.38, 51.99, 45.72, 34.11, 29.78, 29.16, 27.62, 26.18, 10.33.

[0026] IR (KBr) 3455, 3345, 2965, 2953, 2948, 2932, 2913, 2850, 2783, 2749, 1713, 1662, 1587, 1555, 1421, 1285, 1237, 1219, 1184, 1155, 1149, 1128, 793, 753.

[0027] Analysis calculated for $\text{C}_{20}\text{H}_{29}\text{N}_3\text{O}_3$: C, 66.83; H, 8.13; N, 11.69. Found: C, 66.46; H, 8.04; N, 11.58.


Example 2: Irinotecan

[0028] A solution of 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate as prepared in Example 1 (0.359 g, 1.0 mmol) and 14CPT (the compound of formula (I) above) (0.39 g, 1.5 mmol) in 10 ml acetic acid was heated to 115°C for 22 hours. The resulting mixture was distilled under vacuum to yield a black semisolid residue. The residue was dissolved in a 95:5 (v/v) methylene chloride/methanol mixture and chromatographed on 20 g silica-60 (230–400 mesh), eluting with 95:5 (v/v) methylene chloride/methanol (400 ml) and then 92.5:7.5 (v/v) methylene chloride/methanol (600 ml). The resulting product fractions were combined and evaporated to provide a residue, which was then redissolved in 20 ml methylene chloride and washed with saturated aqueous sodium bicarbonate solution (2 x 10 ml). The resulting organic phase was dried over sodium sulfate and evaporated. Ethanol was added and the resulting solution concentrated to a volume of 8 ml before being allowed to crystallize overnight. The solids were filtered and dried to yield 0.243 g of irinotecan (CPT-11 free base) as a pale yellow solid.

[0029] The irinotecan produced as above (0.216 g) was dissolved in 2 ml water and 0.43 ml 1M HCl and heated to 60°C to form a yellow solution. This solution was filtered hot over powdered activated carbon (Darco™ G-60) (0.5 g). The filtrate was cooled and seeded with 5 mg irinotecan hydrochloride crystals and allowed to crystallize overnight. The solids were filtered, washed with water (2 x 1 ml), and suction dried under air to yield 0.123 g of irinotecan hydrochloride trihydrate as pale yellow crystals having a melting point of 259.8°C.


WHAT IS CLAIMED IS:

1. A compound having the formula




or a pharmaceutically acceptable salt thereof, where R^1 is hydrogen, an alkyl, aralkyl, hydroxymethyl, carboxymethyl, acyloxymethyl or trialkylsilyl group, or a group $-CH_2NR^3R^4$ where N is a linking nitrogen atom and where (a) R^3 and R^4 are independently selected from hydrogen and alkyl, alkenyl, hydroxyalkyl and alkoxyalkyl groups; (b) R^3 is hydrogen or an alkyl, alkenyl, hydroxyalkyl or alkoxyalkyl group, and R^4 is $-COR^5$ where R^5 is hydrogen or an alkyl, alkenyl, hydroxyalkyl or alkoxyalkyl group; or (c) R^3 and R^4 taken together with the linking nitrogen atom form a saturated 3- to 7-member heterocyclic group.

2. The compound of Claim 1 where R^1 is an ethyl group.
3. The compound of Claim 1 that is a free base form of 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate.
4. The compound of Claim 1 that is a salt of 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate with an acid selected from hydrochloric, hydrobromic, sulfuric, methanesulfonic, phosphoric, nitric, benzoic, citric, tartaric, fumaric and maleic acids, and mono- and dicarboxylic acids of formula $CH_3-(CH_2)_n-COOH$ and $HOOC-(CH_2)_n-COOH$ where n is 0 to 4.
5. The compound of Claim 1 that is a hydrochloride salt of 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate.
6. A process for preparing irinotecan or a salt thereof, the process comprising a step of reacting 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate or a salt thereof with the compound having the formula



7. Irinotecan or a salt thereof prepared by the process of Claim 6.
8. A process for preparing 7-ethyl-10-hydroxycamptothecin or a salt thereof, the process comprising a first step of reacting 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate or a salt thereof with the compound having the formula



to form irinotecan or a salt thereof; and a second step of hydrolyzing the irinotecan or salt thereof in an acid medium to form 7-ethyl-10-hydroxycamptothecin or a salt thereof.

9. 7-Ethyl-10-hydroxycamptothecin or a salt thereof prepared by the process of Claim 8.
10. A process for preparing 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate, the process comprising a step of reacting 1-(4-hydroxy-2-aminophenyl)-1-propanone with 4-piperidinopiperidinecarbonyl chloride.
11. A drug substance comprising irinotecan and/or at least one salt thereof in a therapeutically effective total amount and 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate and/or at least one salt thereof in a detectable amount.
12. The drug substance of Claim 11 wherein the 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate is present in an amount not greater than about 5% by

weight.

13. The drug substance of Claim 11 wherein the 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate is present in an amount not greater than about 2.5% by weight.
14. The drug substance of Claim 11 wherein the 4-amino-3-propionylphenyl-1,4'-bipiperidine-1'-carboxylate is present in an amount not greater than about 1% by weight.

INTERNATIONAL SEARCH REPORT

Intern: Application No
PCT/US 03/11551

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D211/58 C07D491/22 A61K31/4468 A61K31/4745 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 121 451 A (HENEGAR KEVIN E ET AL) 19 September 2000 (2000-09-19) cited in the application column 21 -column 24 ---	6-10
Y	JOSIEN H ET AL: "A GENERAL SYNTHETIC APPROACH TO THE (20S)-CAMPTOTHECIN FAMILY OF ANTITUMOR AGENTS BY A REGIOCONTROLLED CASCADE RADICAL CYCLIZATION OF ARYL ISONITRILES" CHEMISTRY - A EUROPEAN JOURNAL, VCH PUBLISHERS, US, vol. 4, no. 1, 1998, pages 67-83, XP001015572 ISSN: 0947-6539 scheme 6 -----	6-10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

^o Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

* & * document member of the same patent family

Date of the actual completion of the international search

16 July 2003

Date of mailing of the international search report

28/07/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Seitner, I

INTERNATIONAL SEARCH REPORT

Internationa Application No
PCT/US 03/11551

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 6121451	A	19-09-2000	AT 224899 T 15-10-2002
			AU 717179 B2 16-03-2000
			AU 5527896 A 23-10-1996
			CA 2214793 A1 10-10-1996
			CN 1181083 A , B 06-05-1998
			CZ 9703110 A3 18-03-1998
			DE 69623960 D1 31-10-2002
			DE 69623960 T2 05-06-2003
			DK 835257 T3 03-02-2003
			EP 0835257 A1 15-04-1998
			ES 2183943 T3 01-04-2003
			HU 9801436 A2 28-10-1998
			IL 117684 A 10-02-2002
			JP 11503156 T 23-03-1999
			NO 974608 A 08-12-1997
			NZ 306664 A 29-11-1999
			PL 322651 A1 16-02-1998
			PT 835257 T 31-01-2003
			RU 2164917 C2 10-04-2001
			SI 835257 T1 30-04-2003
			TW 438775 B 07-06-2001
			WO 9631513 A1 10-10-1996
			US 6235907 B1 22-05-2001
			US 6444820 B1 03-09-2002
			ZA 9602747 A 06-04-1998